Reply: Missing ligand model in autologous stem cell transplantation by Leung, W et al.
Letter to the Editor
Reply: Missing ligand model in autologous stem cell transplantation
W Leung*,1,2, R Handgretinger
1,2, V Turner
3 and GA Hale
1,2
1Department of Oncology, St Jude Children’s Research Hospital, Memphis, TN, USA;
2Department of Pediatrics, University of Tennessee Health Science
Center, Memphis, TN, USA;
3Department of Pathology, St Jude Children’s Research Hospital, Memphis, TN, USA
British Journal of Cancer (2008) 98, 854. doi:10.1038/sj.bjc.6604154 www.bjcancer.com
Published online 18 December 2007
& 2008 Cancer Research UK
                  
Sir,
We agree with Stern et al that missing KIR-ligand does not
imply inhibitory KIR–HLA receptor–ligand mismatch. In fact,
2 out of our 16 patients (13%) would have been misclassified using
the analytic approach of Stern et al (one for KIR3DL1–Bw6/6
and the other for KIR2DL1–HLA-C
Asn80/Asn80). The statistical
implication for misclassification and exclusion of patients missing
Bw4 cannot be overemphasised. For example, previous publication
studying the effects of HLA mismatch has already demonstrated
the statistical effect (bias towards null) with misclassification
involving only 2–3 patients among 130 individuals (Leung et al,
2001). Furthermore, exclusion of KIR3DL1–Bw4 from any
examination of KIR–HLA interaction will have similar statistical
effect. For instance in our study, a prominent KIR3DL1 mismatch
effect was observed: six out of the seven patients (86%) with
mismatch involving KIR3DL1 were alive, whereas only two out
of the nine patients (22%) without KIR3DL1 mismatch were alive
(P¼0.01, Figure 1). If the analytic approaches of Stern et al were
used on our cohort, we would have concluded erroneously that
neither inhibitory KIR–HLA receptor–ligand mismatch nor
the number of mismatch pairs had any effect on clinical outcome
(HR for relapse¼0.49 (95% CI: 0.1–2.8), P¼0.43). Therefore, we
agree with Stern et al that our intriguing findings should
be confirmed in large studies, which use biologically appropriate
model, prospective design, uniform conditioning regimen and
graft processing, analyses accounting for confounders such as
disease type or status, and direct assessment of KIR expression
on NK cells providing proof that all patients who are assumed to
possess and express all relevant inhibitory KIRs indeed do so
(Leung et al, 2004, 2005).
REFERENCES
Leung W, Iyengar R, Triplett B, Turner V, Behm FG, Holladay MS, Houston J,
Handgretinger R (2005) Comparison of killer Ig-like receptor genotyping
and phenotyping for selection of allogeneic blood stem cell donors.
J Immunol 174: 6540–6545
Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, Niethammer D,
Handgretinger R (2004) Determinants of antileukemia effects of
allogeneic NK cells. J Immunol 172: 644–650
Leung WH, Turner V, Richardson SL, Benaim E, Hale G, Horwitz EM,
Woodard P, Bowman LC (2001) Effect of HLA class I or class II
incompatibility in pediatric marrow transplantation from unrelated
and related donors. Hum Immunol 62: 399–407
Days after HCT
0 500 1000
0.00
0.25
0.50
0.75
1.00
No KIR3DL1 mismatch (22+4%)
KIR3DL1 mismatch (86+33%)
P=0.01
E
F
S
Figure 1 Event-free survival (EFS) of patients with receptor–ligand
mismatch involving KIR3DL1 and of those with no mismatch.
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